Centre De Lutte Contre Le Cancer Eugene Marquis

At Centre De Lutte Contre Le Cancer Eugene Marquis in Rennes, much of the research focuses on neoplasms and the use of immunotherapy to improve outcomes for patients with advanced cancers. Studies include several common and hard-to-treat diseases, such as melanoma, breast cancer, lung cancer, and head and neck cancer, with the goal of testing new treatment strategies and comparing them with current standards of care.

• Advanced and metastatic melanoma, including cases resistant to prior treatment
• Breast cancer subtypes, especially hormone receptor-positive and HER2-negative disease
• Head and neck squamous cell carcinoma and non-small cell lung cancer
• Research aimed at evaluating new immunotherapy combinations and treatment effectiveness

These trials are helping determine how well newer immune-based approaches can control cancer, extend survival, and support more personalized treatment choices.

The site also has a strong program in digestive system diseases, especially cancers of the liver, biliary tract, colon, and small bowel. Research here is centered on improving treatment effectiveness for patients with advanced or unresectable disease, while also exploring better options around surgery and postoperative care.

• Hepatocellular carcinoma and advanced biliary tract cancers
• Colon carcinoma and small bowel adenocarcinoma
• Studies in digestive system cancers that compare standard therapy with newer treatment approaches
• Trials designed to test whether new combinations can improve response and survival

Overall, this research is aimed at finding more effective ways to treat difficult gastrointestinal cancers and to improve long-term disease control.

Another major area of activity at the Comprehensive Cancer Center Eugne Marquis is research in breast and gynecologic cancers. Trials in this field focus on advanced, recurrent, and high-risk disease, with an emphasis on improving disease-free survival, delaying relapse, and refining endocrine-based and targeted treatment strategies.

• Metastatic breast cancer, including ER-positive, HER2-negative, and triple-negative disease
• Ovarian, fallopian tube, and primary peritoneal cancer
• Research exploring better maintenance and relapse-prevention approaches
• Studies evaluating whether newer targeted therapies can outperform established options

These trials are designed to help define more precise treatment pathways for patients with advanced breast and gynecologic malignancies.

This site is also active in male urogenital diseases and related cancer research, particularly for prostate cancer and renal cell carcinoma. The studies aim to improve disease control in advanced settings and to identify treatment options that better match patient needs and overall fitness for therapy.

• Adenocarcinoma of the prostate and metastatic prostate cancer
• Renal cell carcinoma, including advanced and non-clear cell forms
• Trials comparing newer targeted and hormonal approaches with standard treatment
• Research focused on extending progression-free survival and improving quality of care

By studying both established and emerging therapies, the research program seeks to broaden options for patients with advanced urologic cancers.

A notable part of the research portfolio involves diagnosis and analytical techniques that support more precise cancer care. These studies examine tools such as blood-based tumor DNA testing and advanced imaging to improve early detection, monitor relapse, and better characterize aggressive disease.

• ctDNA-based surveillance for earlier identification of recurrence or risk
• 18F-FDOPA PET imaging in suspected glioma and other brain tumors
• Research on diagnostic methods that can guide treatment selection more accurately
• Studies aimed at improving how clinicians identify high-risk disease

These projects reflect a strong interest in using biomarkers and imaging to make cancer care more individualized and responsive.

The research program at this hospital and cancer center also includes a range of less common solid tumors, showing broad interest in difficult-to-treat cancers across the body. The focus is on evaluating new therapies and determining whether they can improve outcomes where treatment choices are limited.

• Gastrointestinal stromal tumor, advanced solid tumors, and advanced tumors
• Cutaneous squamous cell carcinoma and other advanced skin cancers
• Low grade glioma and selected nervous system diseases
• Trials designed to test treatment activity, safety, and clinical benefit in uncommon cancers

This work supports the development of more effective options for patients with rare or advanced cancers who often have few standard treatments available.

Some studies at Centre De Lutte Contre Le Cancer Eugene Marquis address broader aspects of cancer care, including prevention of complications and optimization of treatment pathways. These trials are important for improving how patients tolerate therapy and for reducing risks linked to cancer and its treatment.

• Thromboprophylaxis research in patients with advanced germ cell tumors
• Studies evaluating how to improve treatment sequencing and maintenance strategies
• Research focused on reducing recurrence and supporting safer cancer care
• Clinical questions related to overall treatment effectiveness and patient outcomes

By combining disease treatment with supportive care questions, this research helps strengthen the practical delivery of modern oncology.